Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


11.09.2017

3 Anticancer Res
2 BJU Int
5 BMC Cancer
3 Br J Cancer
2 Cancer Res
3 Eur Urol
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Magn Reson Imaging
1 J Nucl Med
2 J Urol
1 Lancet Oncol
1 Nat Rev Cancer
1 Nat Rev Urol
1 Oncogene
5 PLoS One
2 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    Anticancer Res. 2017;37:5117-5124.
    PubMed     Text format     Abstract available

  2. WU X, Reinikainen P, Kapanen M, Vierikko T, et al
    Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5027-5032.
    PubMed     Text format     Abstract available

  3. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients.
    Anticancer Res. 2017;37:4961-4965.
    PubMed     Text format     Abstract available


    BJU Int

  4. BAUER RM, Grabbert MT, Klehr B, Gebhartl P, et al
    36-month data for the AdVance XP(R) male sling: results of a prospective multicentre study.
    BJU Int. 2017;119:626-630.
    PubMed     Text format     Abstract available

  5. TAAFFE DR, Buffart LM, Newton RU, Spry N, et al
    Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14008.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. TANAKA N, Nakai Y, Miyake M, Anai S, et al
    Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
    BMC Cancer. 2017;17:616.
    PubMed     Text format     Abstract available

  7. WANG H, Gu L, Wu Y, Feng D, et al
    The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score >/= 7 prostate cancer from group of biopsy-based Gleason score </= 6.
    BMC Cancer. 2017;17:629.
    PubMed     Text format     Abstract available

  8. GONNISSEN A, Isebaert S, Perneel C, McKee CM, et al
    Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer.
    BMC Cancer. 2017;17:634.
    PubMed     Text format     Abstract available

  9. MITRA R, Le TT, Gorjala P, Goodman OB Jr, et al
    Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
    BMC Cancer. 2017;17:631.
    PubMed     Text format     Abstract available

  10. SONG W, Soni V, Soni S, Khera M, et al
    Testosterone inhibits the growth of prostate cancer xenografts in nude mice.
    BMC Cancer. 2017;17:635.
    PubMed     Text format     Abstract available


    Br J Cancer

  11. CYLL K, Ersvaer E, Vlatkovic L, Pradhan M, et al
    Tumour heterogeneity poses a significant challenge to cancer biomarker research.
    Br J Cancer. 2017;117:367-375.
    PubMed     Text format     Abstract available

  12. DEMARK-WAHNEFRIED W, Rais-Bahrami S, Desmond RA, Gordetsky JB, et al
    Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  13. PIROVANO G, Ashton TM, Herbert KJ, Bryant RJ, et al
    TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
    Br J Cancer. 2017;117:503-512.
    PubMed     Text format     Abstract available


    Cancer Res

  14. WEI X, Xu Y, Xu FF, Chaiswing L, et al
    RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
    Cancer Res. 2017;77:1345-1356.
    PubMed     Text format     Abstract available

  15. OH DY, Cham J, Zhang L, Fong G, et al
    Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017;77:1322-1330.
    PubMed     Text format     Abstract available


    Eur Urol

  16. ZHU Y, Sharp A, Anderson CM, Silberstein JL, et al
    Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Aug 30. pii: S0302-2838(17)30695.
    PubMed     Text format     Abstract available

  17. GILLESSEN S, de Bono JS, Sartor O, Omlin AG, et al
    Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30700.
    PubMed     Text format    

  18. VON EYBEN FE, Virgolini I, Roviello G
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30696.
    PubMed     Text format    


    Int J Cancer

  19. ROMAGUERA D, Gracia-Lavedan E, Molinuevo A, de Batlle J, et al
    Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case-control study.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30722.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. ECHEVARRIA MI, Naghavi AO, Abuodeh YA, Ahmed KA, et al
    Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
    Int J Radiat Oncol Biol Phys. 2017;99:378-382.
    PubMed     Text format     Abstract available

  21. PINKAWA M, Berneking V, Schlenter M, Krenkel B, et al
    Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results.
    Int J Radiat Oncol Biol Phys. 2017;99:374-377.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  22. DWIVEDI DK, Kumar R, Dwivedi AK, Bora GS, et al
    Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    J Magn Reson Imaging. 2017 Sep 4. doi: 10.1002/jmri.25850.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. FOSBOL MO, Petersen PM, Kjaer A, Mortensen J, et al
    Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.195677. doi: 10.2967/jnumed.117.195677.
    PubMed     Text format     Abstract available


    J Urol

  24. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  25. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Lancet Oncol

  26. DAS M
    Androgen deprivation therapy for prostate cancer.
    Lancet Oncol. 2017 Sep 1. pii: S1470-2045(17)30670.
    PubMed     Text format    


    Nat Rev Cancer

  27. BRADLEY CA
    Prostate cancer: BET inhibitors - SPOP right there!
    Nat Rev Cancer. 2017 Sep 8. doi: 10.1038/nrc.2017.
    PubMed     Text format    


    Nat Rev Urol

  28. SEDARSKY J, Degon M, Srivastava S, Dobi A, et al
    Ethnicity and ERG frequency in prostate cancer.
    Nat Rev Urol. 2017 Sep 5. doi: 10.1038/nrurol.2017.
    PubMed     Text format     Abstract available


    Oncogene

  29. MCCURDY SR, Pacal M, Ahmad M, Bremner R, et al
    A CDK2 activity signature predicts outcome in CDK2-low cancers.
    Oncogene. 2017;36:2491-2502.
    PubMed     Text format     Abstract available


    PLoS One


  30. Correction: Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2.
    PLoS One. 2017;12:e0184609.
    PubMed     Text format     Abstract available

  31. READY D, Yagiz K, Amin P, Yildiz Y, et al
    Mapping the STK4/Hippo signaling network in prostate cancer cell.
    PLoS One. 2017;12:e0184590.
    PubMed     Text format     Abstract available

  32. GUI B, Hsieh CL, Kantoff PW, Kibel AS, et al
    Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
    PLoS One. 2017;12:e0184166.
    PubMed     Text format     Abstract available

  33. CANESIN G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, et al
    Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
    PLoS One. 2017;12:e0184418.
    PubMed     Text format     Abstract available

  34. LIAO JM, Ommerborn MJ, Clark CR
    Association between features of patient-provider discussions and routine prostate-specific antigen testing.
    PLoS One. 2017;12:e0177687.
    PubMed     Text format     Abstract available


    Prostate

  35. STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
    Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
    Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
    PubMed     Text format     Abstract available

  36. YANG CS, Melhuish TA, Spencer A, Ni L, et al
    The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
    PubMed     Text format     Abstract available


    Urology

  37. DEEBEL NA, Morin JP, Autorino R, Vince R, et al
    Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges.
    Urology. 2017 Sep 4. pii: S0090-4295(17)30906.
    PubMed     Text format     Abstract available

  38. BOESEN L, Norgaard N, Logager V, Balslev I, et al
    Where Do TRUS- and MRI Guided Biopsies Miss Significant Prostate Cancer?
    Urology. 2017 Aug 30. pii: S0090-4295(17)30899.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: